Most Read Articles
Stephen Padilla, 3 days ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
4 days ago
Socioeconomic status, along with other social determinants, appears to influence the long-term outcomes in Asian acute heart failure patients, according to a recent Japan study.
Pearl Toh, 6 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
Jairia Dela Cruz, 3 days ago
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.

Tadalafil does not help lessen ambulatory ability decline in boys with DMD

12 Dec 2017

Tadalafil may not be effective for reducing the decline in ambulatory ability in boys with Duchenne muscular dystrophy (DMD), as shown in a recent study.

The study randomized 331 boys (mean age 9.6 years) with DMD to receive tadalafil 0.3 mg·kg−1·d−1, tadalafil 0.6 mg·kg−1·d−1 or placebo for 48 weeks. Efficacy was assessed using the 6-minute walk distance (6MWD). Secondary efficacy measures were North Star Ambulatory Assessment and timed function tests. Performance of Upper Limb (PUL) was examined as a prespecified exploratory outcome.

Tadalafil did not exert an effect on the primary outcome. The 6MWD after 48 weeks of treatment decreased by 51.0 m with placebo, 64.7 m with low-dose tadalafil (p=0.307 vs placebo) and 59.1 m with high-dose tadalafil (p=0.538 vs placebo). The drug had no effect on secondary outcomes.

In the group of patients aged >10 years, those treated with low-dose tadalafil showed smaller declines in total PUL score and shoulder subscore compared with those who received placebo.  

Drug-related adverse events were reported in 41.4 percent of patients in the placebo group, 50.0 percent in the low-dose tadalafil group and 59.8 percent in the high-dose tadalafil group.

Adverse events were consistent with the known safety profile of tadalafil and the DMD disease state, researchers noted. “Safety monitoring revealed the expected increase in penile erections with tadalafil without priapism.”

Additional research is warranted to determine whether ambulatory decline in DMD can be lessened by initiation of PDE5 inhibition before 7 years of age, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 3 days ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
4 days ago
Socioeconomic status, along with other social determinants, appears to influence the long-term outcomes in Asian acute heart failure patients, according to a recent Japan study.
Pearl Toh, 6 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
Jairia Dela Cruz, 3 days ago
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.